D.E. Shaw & Co
SRNE

D.E. Shaw & Co’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

D.E. Shaw & Co’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,200
Closed -$184K – 5118
2021
Q1 		$184K Buy
+22,200
New +$234K ﹤0.01% 3867

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

D.E. Shaw & Co's SRNE Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 5,106,072 shares — an estimated $4.52M sold.

D.E. Shaw & Co first reported a position in SRNE in Q3 2015 and held it in 21 quarters. The position peaked at $22.5M in Q3 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 5,106,072 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $4.52M.
  • D.E. Shaw & Co first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 21 quarters.
  • D.E. Shaw & Co's Sorrento Therapeutics, Inc. position peaked at $22.5M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.